4D Molecular Therapeutics (FDMT) Competitors $8.83 +0.81 (+10.10%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends FDMT vs. CNTA, IRON, GLPG, RXRX, TARS, NRIX, XNCR, IMCR, ARVN, and KNSAShould you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Centessa Pharmaceuticals (CNTA), Disc Medicine (IRON), Galapagos (GLPG), Recursion Pharmaceuticals (RXRX), Tarsus Pharmaceuticals (TARS), Nurix Therapeutics (NRIX), Xencor (XNCR), Immunocore (IMCR), Arvinas (ARVN), and Kiniksa Pharmaceuticals (KNSA). These companies are all part of the "pharmaceutical products" industry. 4D Molecular Therapeutics vs. Centessa Pharmaceuticals Disc Medicine Galapagos Recursion Pharmaceuticals Tarsus Pharmaceuticals Nurix Therapeutics Xencor Immunocore Arvinas Kiniksa Pharmaceuticals Centessa Pharmaceuticals (NASDAQ:CNTA) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment. Is CNTA or FDMT more profitable? 4D Molecular Therapeutics' return on equity of -28.76% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -52.13% -38.01% 4D Molecular Therapeutics N/A -28.76%-27.07% Do institutionals & insiders have more ownership in CNTA or FDMT? 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 11.6% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 7.3% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, CNTA or FDMT? 4D Molecular Therapeutics has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M264.56-$151.09M-$1.53-10.464D Molecular Therapeutics$20.22M22.70-$100.84M-$2.85-3.10 Do analysts rate CNTA or FDMT? Centessa Pharmaceuticals presently has a consensus target price of $25.83, suggesting a potential upside of 61.46%. 4D Molecular Therapeutics has a consensus target price of $47.00, suggesting a potential upside of 432.28%. Given 4D Molecular Therapeutics' higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.004D Molecular Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Does the MarketBeat Community prefer CNTA or FDMT? 4D Molecular Therapeutics received 18 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 71.21% of users gave 4D Molecular Therapeutics an outperform vote while only 56.86% of users gave Centessa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCentessa PharmaceuticalsOutperform Votes2956.86% Underperform Votes2243.14% 4D Molecular TherapeuticsOutperform Votes4771.21% Underperform Votes1928.79% Does the media prefer CNTA or FDMT? In the previous week, Centessa Pharmaceuticals had 7 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 20 mentions for Centessa Pharmaceuticals and 13 mentions for 4D Molecular Therapeutics. Centessa Pharmaceuticals' average media sentiment score of 0.78 beat 4D Molecular Therapeutics' score of 0.10 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 4 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, CNTA or FDMT? Centessa Pharmaceuticals has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.82, meaning that its stock price is 182% more volatile than the S&P 500. Summary4D Molecular Therapeutics beats Centessa Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Ad Behind the MarketsUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FDMT vs. The Competition Export to ExcelMetric4D Molecular TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$458.90M$2.91B$5.06B$8.66BDividend YieldN/A1.79%5.09%4.06%P/E Ratio-3.1043.08101.8517.37Price / Sales22.70217.681,203.8272.18Price / CashN/A178.0140.9136.36Price / Book1.234.096.335.87Net Income-$100.84M-$42.42M$119.64M$225.66M7 Day Performance8.74%-10.63%-5.12%-1.34%1 Month Performance1.96%-6.02%-3.21%1.00%1 Year Performance-19.95%26.36%32.52%25.27% 4D Molecular Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FDMT4D Molecular Therapeutics2.9925 of 5 stars$8.83+10.1%$47.00+432.3%-19.9%$408.19M$20.72M-3.10201Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageCNTACentessa Pharmaceuticals3.8575 of 5 stars$16.00-8.6%N/A+129.2%$1.81B$6.85M-10.4672Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageIRONDisc Medicine3.1956 of 5 stars$59.46-2.0%N/A+23.0%$1.77BN/A-14.9478Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageGLPGGalapagos1.6033 of 5 stars$26.80-3.9%N/A-27.5%$1.77B$259.40M0.001,123Short Interest ↓High Trading VolumeRXRXRecursion Pharmaceuticals2.1209 of 5 stars$6.18-10.7%N/A-7.4%$1.74B$64.60M-4.04400Insider SellingTARSTarsus Pharmaceuticals1.7501 of 5 stars$44.83-3.9%N/A+152.8%$1.71B$83.37M-11.7750Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeNRIXNurix Therapeutics2.6769 of 5 stars$22.92-14.7%N/A+277.6%$1.62B$76.99M-7.88300Positive NewsXNCRXencor3.604 of 5 stars$23.07-1.8%N/A+24.4%$1.61B$168.34M-7.21280Insider SellingHigh Trading VolumeIMCRImmunocore2.9264 of 5 stars$31.59-3.2%N/A-32.6%$1.58B$296.31M-33.25497Gap DownARVNArvinas2.3286 of 5 stars$22.48-9.8%N/A+8.1%$1.54B$78.50M-4.81445Short Interest ↓KNSAKiniksa Pharmaceuticals2.2751 of 5 stars$21.29-2.4%N/A+37.4%$1.54B$384.10M-152.06220 Related Companies and Tools Related Companies CNTA Alternatives IRON Alternatives GLPG Alternatives RXRX Alternatives TARS Alternatives NRIX Alternatives XNCR Alternatives IMCR Alternatives ARVN Alternatives KNSA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FDMT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FDMT Stock Alerts